AstraZeneca's new hypertension drug successfully completes Phase III trial.

On July 15, Interface News learned from AstraZeneca that its investigational drug Baxdrostat achieved primary and all secondary endpoints in the BaxHTN phase III clinical trial for patients with uncontrolled or difficult-to-treat hypertension. According to the positive results of the BaxHTN phase III trial, compared to placebo, both doses of Baxdrostat showed statistically and clinically significant reductions in seated systolic blood pressure after 12 weeks of treatment, and the trial also successfully achieved all secondary endpoints. Baxdrostat is an investigational highly selective aldosterone synthase inhibitor that targets hormones that lead to increased blood pressure and cardiovascular and renal risk. Currently, the drug is being evaluated in clinical trials as monotherapy for hypertension and primary aldosteronism.